Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen

Tzu Chi Medical Journal

Volumn 25, Issue 2, 2013, Pages 75-81

  Tseng, Tai Chung ^a,b,c   Kao, Jia Horng ^b,d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

HBsAg; HBV; HCC; Hepatitis; QHBsAg

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER RISK; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE DURATION; ENVELOPE GENE; EXTRACELLULAR MATRIX; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PACIFIC ISLANDS; PROGNOSIS; REVIEW; SEROCONVERSION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84878116587     PISSN: 10163190     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcmj.2013.03.005     Document Type: Review

References (61)

1. Kao J.H., Chen P.J., Chen D.S. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res 2010, 108:21-72.
2. Kao J.H., Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403.
3. Blumberg B.S., Sutnick A.I., London W.T. Hepatitis and leukemia: their relation to Australia antigen. Bull N Y Acad Med 1968, 44:1566-1586.
4. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
5. Iloeje U.H., Yang H.I., Jen C.L., Su J., Wang L.Y., You S.L., et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007, 5:921-931.
6. Tseng T.C., Liu C.J., Su T.H., Wang C.C., Chen C.L., Chen P.J., et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011, 141:517-525. e2.
7. Tseng T.C., Kao J.H. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. JGastroenterol 2013, 48:13-21.
8. Hsu H.Y., Chang M.H., Chen D.S., Lee C.Y., Sung J.L. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. JMed Virol 1986, 18:301-307.
9. Chen D.S. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993, 262:369-370.
10. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
11. Liaw Y.F., Lau G.K., Kao J.H., Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010, 55:2727-2734.
12. Chu C.M., Liaw Y.F. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007, 133:1458-1465.
13. Chen Y.C., Chu C.M., Liaw Y.F. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010, 51:435-444.
14. Tseng T.C., Liu C.J., Chen C.L., Wang C.C., Su T.H., Kuo S.F., et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. JInfect Dis 2012, 205:54-63.
15. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
16. Tai D.I., Lin S.M., Sheen I.S., Chu C.M., Lin D.Y., Liaw Y.F. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009, 49:1859-1867.
17. Chu C.M., Hung S.J., Lin J., Tai D.I., Liaw Y.F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004, 116:829-834.
18. Chu C.M., Liaw Y.F. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010, 15:133-143.
19. Chan H.L., Wong V.W., Wong G.L., Tse C.H., Chan H.Y., Sung J.J. Alongitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010, 52:1232-1241.
20. Nguyen T., Thompson A.J., Bowden S., Croagh C., Bell S., Desmond P.V., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. JHepatol 2010, 52:508-513.
21. Jaroszewicz J., Calle Serrano B., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. JHepatol 2010, 52:514-522.
22. Liaw Y.F., Sheen I.S., Chen T.J., Chu C.M., Pao C.C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627-631.
23. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
24. McMahon B.J., Holck P., Bulkow L., Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
25. Kim J.H., Lee J.H., Park S.J., Bae M.H., Kim do Y., Kim J.K., et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology 2008, 55:578-581.
26. Liu J., Yang H.I., Lee M.H., Lu S.N., Jen C.L., Wang L.Y., et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010, 139:474-482.
27. Tseng T.C., Liu C.J., Yang H.C., Su T.H., Wang C.C., Chen C.L., et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012, 55:68-76.
28. Chen Y.C., Sheen I.S., Chu C.M., Liaw Y.F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
29. Fattovich G., Giustina G., Sanchez-Tapias J., Quero C., Mas A., Olivotto P.G., et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998, 93:896-900.
30. Huo T.I., Wu J.C., Lee P.C., Chau G.Y., Lui W.Y., Tsay S.H., et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998, 28:231-236.
31. Yuen M.F., Wong D.K., Sablon E., Tse E., Ng I.O., Yuan H.J., et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004, 39:1694-1701.
32. Chan H.L., Wong G.L., Tse C.H., Chan H.Y., Wong V.W. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. JInfect Dis 2011, 204:408-414.
33. Seto W.K., Wong D.K., Fung J., Hung I.F., Fong D.Y., Yuen J.C., et al. Alarge case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012, 56:812-819.
34. Chang M.H., Chiu Y.C., Wu J.F., Lin C.Y., Ni Y.H., Chen H.L., et al. Spontaneous clearance of hepatitis B surface antigen during the natural history of chronic hepatitis B virus infection. Hepatology 2011, 54. Abstract 731.
35. Chen Y.C., Jeng W.J., Chu C.M., Liaw Y.F. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2012, 10:297-302.
36. Liu J., Lee M.H., Batrla-Utermann R., Jan C.L., Iloeje U.H., Lu S.N., et al. Apredictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. JHepatol 2012 Dec 13, [Epub ahead of print].
37. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
38. Liaw Y.F., Kao J.H., Piratvisuth T., Chan H.L., Chien R.N., Liu C.J., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
39. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185. European Association for the Study of the Liver.
40. Wong V.W., Chan S.L., Mo F., Chan T.C., Loong H.H., Wong G.L., et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. JClin Oncol 2010, 28:1660-1665.
41. Yuen M.F., Tanaka Y., Fong D.Y., Fung J., Wong D.K., Yuen J.C., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. JHepatol 2009, 50:80-88.
42. Chen C.H., Hung C.H., Lee C.M., Hu T.H., Wang J.H., Wang J.C., et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007, 133:1466-1474.
43. Liu C.J., Chen B.F., Chen P.J., Lai M.Y., Huang W.L., Kao J.H., et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. JInfect Dis 2006, 193:1258-1265.
44. Liu C.J., Chen B.F., Chen P.J., Lai M.Y., Huang W.L., Kao J.H., et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. JInfect Dis 2006, 194:594-599.
45. Chen G., Lin W., Shen F., Iloeje U.H., London W.T., Evans A.A. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006, 101:1797-1803.
46. Yu M.W., Yeh S.H., Chen P.J., Liaw Y.F., Lin C.L., Liu C.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. JNatl Cancer Inst 2005, 97:265-272.
47. Tseng T.C., Liu C.J., Yang H.C., Su T.H., Wang C.C., Chen C.L., et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012, 142:1140-1149. e3.
48. Chen J.D., Yang H.I., Iloeje U.H., You S.L., Lu S.N., Wang L.Y., et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010, 138:1747-1754.
49. Chen C.J., Lee M.H., Jessica L., Ricard B.-U., Chin-Lan J., Uchenna I., et al. Quantitative serum levels of hepatitis B virus DNA and surface antigen are independent risk predictors of hepatocellular carcinoma. Hepatology 2011, 54. Abstract 1095.
50. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
51. Tseng T.C., Liu C.J., Yang H.C., Su T.H., Wang C.C., Chen C.L., et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads. Hepatology 2013, 57:441-450.
52. Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.
53. Yang H.I., Sherman M., Su J., Chen P.J., Liaw Y.F., Iloeje U.H., et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. JClin Oncol 2010, 28:2437-2444.
54. Yang H.I., Yuen M.F., Chan H.L., Han K.H., Chen P.J., Kim D.Y., et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011, 12:568-574.
55. Liaw Y.F., Jia J.D., Chan H.L., Han K.H., Tanwandee T., Chuang W.L., et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011, 54:1591-1599.
56. Sonneveld M.J., Rijckborst V., Boucher C.A., Hansen B.E., Janssen H.L. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52:1251-1257.
57. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
58. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
59. Marcellin P., Bonino F., Lau G.K., Farci P., Yurdaydin C., Piratvisuth T., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136:2169-2179. e1-4.
60. Tseng T.C., Liu C.J., Su T.H., Yang H.C., Wang C.C., Chen C.L., et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. JInfect Dis 2012, 206:1521-1531.
61. Reijnders J.G., Perquin M.J., Zhang N., Hansen B.E., Janssen H.L. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010, 139:491-498.